amcure

amcure is engaged in the research and development of compounds for angiogenesis and metastasis inhibition.

amcure, a spin-off from the Karlsruhe Institute of Technology, develops AM001 as first-in-class compound. AM001’s mode of action differs fundamentally from known experimental or approved compounds for the inhibition of angiogenesis and metastasis in cancer therapy, which in most cases either address only a single RTK or target multiple RTKs as broadband inhibitors. By its novel targeting strategy AM001 combines the advantages of receptor specificity and broadband inhibition. Application area for AM001 will be highly metastasizing cancer types with a focus on pancreatic cancer.